文献速递脑血管病外科

FRED X血流导向装置治疗颅内动脉瘤的长期安全性与有效性:一项154例患者的多中心研究

Long-term safety and efficacy of the FRED X flow diverter for intracranial aneurysms: a multicenter study of 154 patients.
PubMed 文献 · J Neurosurg · 2025-02-28

本研究纳入美国6家高容量中心2022年2月至2024年2月接受FRED X治疗的154例患者共162个动脉瘤,评估其疗效、安全性和长期结局。装置部署满意率≥99.3%,出院时95.5%患者功能独立,动脉瘤充分闭塞率从6个月的84.2%变为12个月的83.5%,支架内狭窄率下降。

要点

  • FRED X部署满意率≥99.3%,壁贴靠和瘤颈覆盖良好。
  • 出院时95.5%患者功能独立(改良Rankin量表评分0-2分)。
  • 动脉瘤充分闭塞率6个月为84.2%,12个月为83.5%,支架内狭窄率下降。

核心结论

  • FRED X部署简便,安全性可接受,手术并发症率低,随访结局良好。
  • 动脉瘤闭塞率随时间推移而增加,支架相关并发症随之减少。

研究设计与样本

  • 多中心队列研究,纳入美国6家高容量中心2022年2月至2024年2月接受FRED X治疗的颅内动脉瘤患者。
  • 共154例患者、162个动脉瘤,使用164枚FRED X装置。
  • 收集人口学、临床表现和手术疗效数据,在6个月和12个月评估血管造影和临床随访结局。

主要发现

  • 队列中女性占81.8%,平均年龄56.8岁。
  • 装置部署满意率≥99.3%,壁贴靠和瘤颈覆盖良好。
  • 147例(95.5%)患者出院时功能独立(改良Rankin量表评分0-2分)。
  • 动脉瘤充分闭塞率(Raymond-Roy闭塞量表评分I或II)从6个月的84.2%变为12个月随访的83.5%,支架内狭窄率下降。
  • 所有(100%)接受随访的患者在6个月时功能独立,12个月时95.9%功能独立。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Flow-Redirection Endoluminal Device X (FRED X) is a newer generation flow diverter with surface modifications aimed at minimizing thrombogenicity. At present, data on its long-term efficacy are limited. This multicenter study presents the largest series within the United States describing the device's efficacy, safety, and long-term outcomes in treating cerebral aneurysms of varying morphology. METHODS: Patients treated with the FRED X for a cerebral aneurysm between February 2022 and February 2024 at 6 high-volume centers across the United States were included. Data were collected regarding demographics, clinical presentation, and procedural efficacy. Angiographic and clinical follow-up outcomes were assessed at 6 and 12 months. RESULTS: A total of 154 patients with 162 aneurysms were treated with 164 FRED X devices over the study period. Overall, 81.8% of the cohort was female with a mean age of 56.8 years. The authors observed satisfactory rates (≥ 99.3%) of device deployment and good wall apposition and neck coverage. One hundred forty-seven (95.5%) patients were functionally independent at discharge (modified Rankin Scale scores 0-2). Rates of adequate occlusion (Raymond-Roy Occlusion Scale score I or II) increased from 84.2% at 6 months to 83.5% at the 12-month follow-up, while rates of in-stent stenosis decreased. All patients (100%) who underwent follow-up were functionally independent at 6 months, and 95.9% were functionally independent at 12 months. CONCLUSIONS: This multicenter cohort study demonstrates the ease of FRED X deployment with an adequate safety profile, with low rates of procedural complications and favorable outcomes on follow-up. Rates of aneurysm occlusion increased over time, with a subsequent decrease in stent-associated complications.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Roy JM, El Naamani K, Amaravadi C, et al. Long-term safety and efficacy of the FRED X flow diverter for intracranial aneurysms: a multicenter study of 154 patients. J Neurosurg. 2025. PMID: 40020234. doi:10.3171/2024.10.JNS241233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。